找到最佳平衡点：靶向肿瘤中的 RAS，同时保护正常组织。

Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.

机构信息

Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA.

出版信息

Cancer Cell. 2024 Jun 10;42(6):943-945. doi: 10.1016/j.ccell.2024.05.020.

DOI:10.1016/j.ccell.2024.05.020

PMID:38861932

Abstract

The development of mutant-selective KRAS inhibitors represents a major therapeutic advance; however, patients can develop resistance through feedback mechanisms and genetic alterations in the RAS pathway. Three publications in Nature and Cancer Discovery describe a promising RAS(ON) multi-selective inhibitor that simultaneously targets oncogenic RAS and multiple potential resistance mechanisms while sparing normal tissue.

摘要

突变体选择性 KRAS 抑制剂的开发代表了重大的治疗进展；然而，患者可能会通过反馈机制和 RAS 通路中的遗传改变产生耐药性。《自然》和《癌症发现》杂志上的三篇论文描述了一种很有前途的 RAS(ON)多选择性抑制剂，它可以同时针对致癌性 RAS 和多种潜在的耐药机制，同时保护正常组织。